Health ❯ Healthcare

Side Effects

Medication Risks Medication Side Effects Gastrointestinal Issues Adverse Reactions Drug Interactions Drug Safety Common Side Effects Drug Side Effects Vaccine Reactions Drug Reactions Vaccine Side Effects Medication Interactions Medication Tolerability Medication Discontinuation Neuropathy Gut-related Issues Aspirin Side Effects Hair Loss Pancreatitis FluMist Weight Loss Vision Problems Clinical Trials Omeprazole Topical Treatments Drug Tolerability Nausea Treatment Efficacy Statin Side Effects Gastrointestinal Effects Taste Changes Amlodipine Side Effects Patient Experiences Gastrointestinal Symptoms Digestive Issues Stomatitis Patient Care Impfreaktionen Reactogenicity Medication Adverse Effects Adverse Effects GLP-1 Medications Medication Safety Serious Side Effects Respiratory Issues Pruritus Opioid Side Effects Epinephrine Medication Effects Vaccines Neuropsychiatric Effects Skin Reactions Emergency Contraceptive Pills Vision Loss Treatment Side Effects Adverse Events

Honey Energy Supplement Recalled After FDA Finds Undeclared ED Drug

Regulators say testing found undisclosed tadalafil, posing risks to users on nitrate medications.

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Conditional EU Approval for Anktiva in BCG-Unresponsive Bladder Cancer

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Tufts Chemists Unveil Four-Receptor Obesity Drug to Challenge Bariatric Surgery

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations

FDA Warns of Rare Severe Itching After Stopping Common Allergy Medications